Patrys Ltd (ASX: PAB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Patrys Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $70.46 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 2.06 billion
Earnings per share -0.002
Dividend per share N/A
Year To Date Return 58.99%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Patrys Ltd (ASX: PAB)
Latest News

PAB ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Patrys Ltd

Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 and PAT-DX1-NP, and PAT-LM1. Its lead technology is Deoxymab 3E10,a DNA damage repair (DDR) antibody which penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.

PAB Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
03 Dec 2021 $0.04 $0.00 0.00% 3,575,643 $0.04 $0.04 $0.04
02 Dec 2021 $0.04 $0.00 0.00% 2,469,444 $0.04 $0.04 $0.04
01 Dec 2021 $0.04 $0.00 0.00% 1,668,028 $0.04 $0.04 $0.04
30 Nov 2021 $0.04 $0.00 0.00% 3,359,787 $0.04 $0.04 $0.04
29 Nov 2021 $0.04 $0.00 0.00% 5,801,906 $0.04 $0.04 $0.04
26 Nov 2021 $0.04 $0.00 0.00% 3,600,632 $0.04 $0.04 $0.04
25 Nov 2021 $0.04 $0.00 0.00% 8,011,436 $0.04 $0.04 $0.04
24 Nov 2021 $0.04 $0.00 0.00% 2,674,164 $0.04 $0.04 $0.04
23 Nov 2021 $0.04 $0.00 0.00% 11,191,401 $0.04 $0.04 $0.04
22 Nov 2021 $0.04 $0.00 0.00% 5,544,217 $0.04 $0.04 $0.04
19 Nov 2021 $0.04 $0.00 0.00% 2,426,346 $0.04 $0.04 $0.04
18 Nov 2021 $0.04 $0.00 0.00% 4,346,799 $0.04 $0.04 $0.04
17 Nov 2021 $0.04 $0.00 0.00% 5,843,780 $0.04 $0.04 $0.04
16 Nov 2021 $0.04 $0.00 0.00% 2,965,438 $0.04 $0.04 $0.04
15 Nov 2021 $0.04 $0.00 0.00% 9,035,599 $0.04 $0.04 $0.04
12 Nov 2021 $0.04 $0.01 27.03% 20,642,887 $0.04 $0.04 $0.04
11 Nov 2021 $0.04 $0.00 0.00% 4,099,714 $0.04 $0.04 $0.04
10 Nov 2021 $0.04 $0.00 0.00% 5,431,459 $0.04 $0.04 $0.04
09 Nov 2021 $0.04 $0.00 0.00% 5,979,026 $0.04 $0.04 $0.04
08 Nov 2021 $0.04 $0.00 0.00% 12,710,393 $0.04 $0.04 $0.04
05 Nov 2021 $0.04 $0.00 0.00% 2,992,155 $0.04 $0.04 $0.04
04 Nov 2021 $0.04 $0.00 0.00% 3,309,097 $0.04 $0.04 $0.04

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
18 Nov 2021 James Campbell Issued 25 $1,000,000
Issue of options.
02 Sep 2021 James Campbell Exercise 9 $64,800
Exercise of options.
02 Sep 2021 James Campbell Buy 9 $64,800
Exercise of options.
18 Dec 2020 John Read Issued 1 $21,600
Issue of options.
18 Dec 2020 Michael Stork Issued 800 $14,400
Issue of options.
18 Dec 2020 Suzy Jones Issued 800 $14,400
Issue of options.
18 Dec 2020 Pamela Klein Issued 800 $14,400
Issue of options.
18 Dec 2020 James Campbell Issued 11 $198,000
Issue of options.
15 Dec 2020 James Campbell Issued 401 $7,227
Rights issue.
15 Dec 2020 James Campbell Issued 198 $3,961
Rights issue.
15 Dec 2020 James Campbell Issued 1 $20,131
Rights issue.
15 Dec 2020 John Read Issued 416 $7,500
Rights issue.
15 Dec 2020 John Read Issued 86 $1,729
Rights issue.
15 Dec 2020 John Read Issued 1 $23,270
Rights issue.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr John Douglas Read Non-Executive ChairmanNon-Executive Director May 2007
Mr Read is an experienced Chairman and Director in public, private and government organisations. Through his career in venture capital, private equity and commercialisation he has gained experience in the formation and growth of emerging companies with an emphasis on commercial entities that provide broad societal benefits. He is a member of the Risk committee.
Dr James Campbell Chief Executive OfficerManaging Director Nov 2014
Dr Campbell has more than 20 years of international biotechnology research, management and experience and has been involved in the creation and/or transformation of multiple Australian and international biotechnology companies. Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS). In 2011 ChemGenex was sold to Cephalon for $230M. Dr Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with capital raising and partnering negotiations. Dr. Campbell sits on the Board of AusBiotech, Australia's peak industry body for biotechnology
Mr Michael Stork Non-Executive Deputy ChairmanNon-Executive Director Feb 2007
Mr Stork is the Managing Director of Stork Holdings Ltd, an Investment Holding company active in the Canadian technology startup sector. Mr Stork was on the Board of Governors of the University of Waterloo and is the Chairman of the Waterloo Accelerator Centre, a technology company incubator affiliated with the University. He was the Chairman of Spartan Biosciences Inc., an Ottawa based DNA analytics company, the Chairman of Dejero Labs Inc., a Waterloo based broadcast technology company, and active on the Boards of a number of other leading Canadian technology start-up companies. He is Chair of Risk committee.
Ms Suzy Jones Non-Executive Director Dec 2011
Ms Jones is Founder and Managing Partner of DNA Ink LLC, a life sciences advisory firm in San Francisco. DNA Ink provides corporate strategic guidance to its clients. Prior to starting her own firm, Ms Jones spent 20 years at Genentech where she served in many roles in Business Development, Product Development and Immunology Research. She managed several products during this time including Rituxan, the first monoclonal antibody launched to treat cancer. Ms. Jones has very extensive networks within the pharmaceutical and biotech companies and VC community in North America. Ms. Jones is a Non-Executive Director of Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. She is a member of the Risk committee.
Dr Pamela M Klein Non-Executive Director Oct 2019
Dr Klein has more than 20 years of experience in the oncology and biopharmaceutical industry. She is currently on the Board of Directors for Argenx, a dual-listed (Euronext Brussels and NASDAQ), clinical-stage therapeutic antibody company developing novel drugs in the areas of cancer and severe autoimmune disease. She is also on the Board of F-Star Therapeutics, and Jiya Acquisition Corp. Ms.Klein is the Principal and Founder of PMK BioResearch, which offers strategic consulting in oncology drug development.
Mr Stefan Ross Company Secretary Oct 2021
-
Stefan Ross Company Secretary
-
Allen Ebens Scientific Advisor
-
Peter Ordentlich Scientific Advisor
-
Deanne Greenwood Vice President Business Development & Intellectual Property
-
Valentina Dubljevic Vice President Scientific & Clinical Development
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
National Nominees Limited+B2:B21 174,485,718 9.59%
Dr Dax Marcus Calder 110,000,000 6.05%
Stork Holdings 2010 Ltd 98,773,814 5.43%
Dax Calder Pty Ltd 60,000,000 3.30%
Mr Raymond Laurence Carroll 50,000,000 2.75%
Kemast Investments Pty Ltd <Km Stokes S/F No 1 A/C> 36,751,635 2.02%
Marginata Pty Ltd <Roy Bolton Super Fund A/C> 31,000,000 1.70%
Mr Mladen Marusic 30,000,000 1.65%
Staffwear Pty Ltd <Dax Calder Super Fund A/C> 27,000,000 1.48%
Lgl Trustees Limited <The Konda Family A/C> 26,499,994 1.46%
Lgl Trustees Limited <Mk Pension Plan 473278 A/C> 20,823,529 1.14%
Estelleanne Pty Ltd 20,500,000 1.13%
Yale University 16,116,324 0.89%
Citicorp Nominees Pty Limited 13,855,219 0.76%
Valui Pty Ltd <Fortis Super Fund A/C> 12,250,012 0.67%
Ms Karin Jones 11,595,961 0.64%
Mr Xiaoke Xie 10,000,000 0.55%
Edstop Pty Limited <Superannuation Fund A/C> 9,115,223 0.50%
Mr Steven James Streicher 8,400,000 0.46%
Mr Vinh Tran 7,485,500 0.41%

Profile

since

Note